EBF factors drive expression of multiple classes of target genes governing neuronal development by Green, Yangsook S & Vetter, Monica L
RESEARCH ARTICLE Open Access
EBF factors drive expression of multiple classes of
target genes governing neuronal development
Yangsook S Green and Monica L Vetter
*
Abstract
Background: Early B cell factor (EBF) family members are transcription factors known to have important roles in
several aspects of vertebrate neurogenesis, including commitment, migration and differentiation. Knowledge of
how EBF family members contribute to neurogenesis is limited by a lack of detailed understanding of genes that
are transcriptionally regulated by these factors.
Results: We performed a microarray screen in Xenopus animal caps to search for targets of EBF transcriptional
activity, and identified candidate targets with multiple roles, including transcription factors of several classes. We
determined that, among the most upregulated candidate genes with expected neuronal functions, most require
EBF activity for some or all of their expression, and most have overlapping expression with ebf genes. We also
found that the candidate target genes that had the most strongly overlapping expression patterns with ebf genes
were predicted to be direct transcriptional targets of EBF transcriptional activity.
Conclusions: The identification of candidate targets that are transcription factor genes, including nscl-1, emx1 and
aml1, improves our understanding of how EBF proteins participate in the hierarchy of transcription control during
neuronal development, and suggests novel mechanisms by which EBF activity promotes migration and
differentiation. Other candidate targets, including pcdh8 and kcnk5, expand our knowledge of the types of terminal
differentiated neuronal functions that EBF proteins regulate.
Background
Throughout animal development, many processes must
occur coordinately, including patterning, commitment, dif-
ferentiation and migration of progenitor cells. In the ner-
vous system in particular, these processes are exceedingly
complex and depend on the coordinated expression of
many sets of genes. A detailed understanding of gene reg-
ulation, including knowledge of the hierarchy of transcrip-
tional activity and the types of genes that different
transcription factors target, is therefore a critical founda-
tion for understanding nervous system development. One
group of transcription factors expressed strongly in the
developing nervous system is the early B cell factor (EBF;
also called Collier/Olf/Ebf (COE), and Olf/Ebf (O/E))
family of zinc finger helix-loop-helix proteins.
The EBF family includes EBF1, 2, 3 and O/E-4 in mam-
mals [1-6], with EBF2 and EBF3 being the known family
members in Xenopus [7,8], and ZCOE2 a family member
in zebrafish [9]. Invertebrate members of this family
include Collier in Drosophila, and UNC-3 in Caenorhab-
ditis elegans [10,11]. EBF family proteins contain a DNA
binding domain (a zinc finger coordination motif), which
can also participate in dimerization and transactivation,
an atypical helix-loop-helix domain, which is critical for
formation of homo- and heterodimers, and a carboxy-
terminal domain, which is important for transactivation
[2,4,12].
EBF proteins influence multiple processes during devel-
opment of multiple lineages, including neurons (reviewed
in [13,14]). One of their functions is a role in stabilizing
neuronal cell commitment. For example, Dubois et al.[ 7 ]
showed that EBF2 can affect neuronal progenitor cell
commitment in early Xenopus embryos by reinforcing
the expression of the proneural basic helix-loop-helix
(bHLH) transcription factor NGNR-1, and by maintain-
ing the expression of delta1.I na d d i t i o n ,i nd e v e l o p i n g
chick spinal cord, electroporated mouse Ebf1 drives
expression of Ngn1 and Ngn2 [15]. * Correspondence: monica.vetter@neuro.utah.edu
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differentiation. For example, overexpression of ebf2 and
ebf3 leads to ectopic expression of neuronal-specific
markers like n-tubulin and nf-m in Xenopus embryos
[7,8], suggesting that EBF2 and EBF3 may drive specific
aspects of the neuronal differentiation program. Consis-
tent with this, in Ebf1 null mouse striatum, early neuro-
nal cells show abnormal expression of several genes,
indicating disruption of the process of differentiation
[16]. EBF proteins have also been shown to regulate
aspects of cell differentiation in both Drosophila and
C. elegans ventral nerve cord [17,18], as well as in early
chick spinal cord, where electroporated mouse Ebf1 pro-
motes expression of numerous neuronal markers [15].
EBF proteins have been shown to regulate neurite for-
mation and axon guidance, including thalamocortical
fibers in the mouse lateral ganglionic eminence [16,19],
olfactory axons projecting to the mouse olfactory bulb
[20], as well as motor neurons in C. elegans [11]. EBF pro-
teins also are critical for neuronal cell migration. For
example, EBF factors regulate the migration of gonadotro-
pin releasing hormone (GnRH-1)-synthesizing neurons
from the olfactory epithelium to the hypothalamus [21],
the migration of Purkinje neurons from the anterior corti-
cal transitory zone to beneath the external granular layer
in cerebellar cortex [22], and the migration of facial bran-
chiomotor neurons in the hindbrain [23]. Furthermore,
when Ebf1 is misexpressed in chick spinal cord, neuroe-
pithelial progenitors migrate toward the mantle layer faster
than normal, and the expression levels of NF and R-
cadherin are upregulated [15].
Ebf genes are strongly expressed in differentiating cen-
tral and peripheral neurons throughout development
[1,7,8,24], and clearly govern diverse aspects of neuronal
development. However, it is not fully understood how
these functions are executed since there has not pre-
v i o u s l yb e e nas y s t e m a t i ca n a l y s i so fE B Ft r a n s c r i p t i o n a l
targets involved in neuronal development. The goals of
this study were as follows. First, we performed a microar-
ray analysis to identify candidate targets of EBF3 activity
in the developing Xenopus nervous system. Second, we
analyzed the expression of the candidate targets, to com-
pare their expression with the ebf genes and to gain an
understanding of where in the embryo they may function.
Third, we performed gain- and loss-of-function studies of
EBF2 and EBF3 in Xenopus embryos to analyze in vivo
the dependence of the discovered candidate targets on
EBF activity, and to confirm the microarray results in
vivo. Finally, we assessed which candidate target genes
are likely to be direct targets of EBF3, and which are
indirect targets, to better understand the hierarchy of
transcriptional control by EBF proteins. Many genes pre-
viously demonstrated to be required for neuronal devel-
opment are strongly upregulated by EBF, but were not
previously known to be targets of EBF transcriptional
activity. These targets include transcription factors, cell
structural proteins, an ion channel protein, and a gene
involved in transforming growth factor (TGF)-beta sig-
naling. The variety of targets found expands our knowl-
edge of the kinds of processes EBF proteins regulate, and
reinforces the idea that EBF proteins can influence many
aspects of neuronal development because they direct
expression of several different functional classes of genes.
The discovered candidate targets open a new window to
understanding the broader scope of EBF functions.
Materials and methods
Generation of hormone-inducible constructs
To generate hormone-inducible constructs, a hormone-
binding domain of the human glucocorticoid receptor
(hGR) was fused to the coding region of Xenopus ebf3 (or
ebf2), with a myc tag epitope between hGR and the coding
region (Additional file 1A) [25,26]. The ebf3 coding region
w a so b t a i n e db ye x c i s i o nf r o mp B S - X e b f 3[ 8 ]w i t ht h e
restriction enzyme DraI, which produces a DNA fragment
with blunt ends. The hormone-binding domain was
obtained from the pCS2+hGR-MT vector (hGR with myc
tag) by cutting with XbaI and treatment with Klenow (Pro-
mega, Madison, WI, USA) to generate blunt ends followed
by dephosphorylation of the 3’ ends with CIP (New Eng-
land Biolabs, Ipswich, MA, USA). The excised ebf3 was
then subcloned into the pCS2+hGR-MT vector. To gener-
ate hGR-XEBF2 construct, pBS-Xebf2 [8] was used as a
template and the following primers containing XhoI and
XbaI sites were used to amplify ebf2:5 ’-GGCCCTCGA-
GATGGATCCAATCCA-3’ and 5’-GGCCTCTAGATT-
CACATGGGCACC-3’ (residues in italics are XhoI and
XbaI sites, respectively; bold sequences are the ebf2
sequence). The amplified products were digested with
XhoI and XbaI and subcloned into the pCS2+hGR-MT
vector. Following sequence verification, the in vivo expres-
sion of these fusion proteins was verified by injecting
capped mRNAs into Xenopus embryos at the one-cell
stage and then performing western blotting with lysates of
gastrula stage embryos with 9E10 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), which recognizes
the myc epitope (data not shown).
Microinjection of RNA and morpholinos
The following constructs were used as DNA templates
to make capped mRNA: pCS2+Noggin [27], pCS2+hGR
[28], pCS2+hGR-MT-Xebf2, pCS2+hGR-MT-Xebf3,
pCS2+MT-DN-Xebf, and pCS2+nbgal [29]. Capped
mRNA was generated in vitro using the Message mMa-
chine kit (Ambion, Austin, TX, USA). Antisense mor-
pholino oligonucleotides (MO) were designed by Gene
Tools (Philomath, OR, USA), and directed against
a region at or near the translational start site of ebf2
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(5’-GTATATTTTCCTGAATCCCAAACAT-3’).
For microarray experiments, 1 ng of hGR-XEBF3 mRNA
and 0.2 ng Noggin mRNA were co-injected into Xenopus
embryos at the one-cell stage. Alternatively, 0.4 ng hGR
mRNA and 0.2 ng Noggin mRNA were co-injected in con-
trol embryos. At stage 9, animal caps were dissected from
the embryo, using either a Gastromaster or a hypodermic
needle tip. Animal caps were treated with 30 μM dexa-
methasone (DEX) in 1× Marc’s modified Ringer solution
(MMR) for 4.5 hours before harvesting of total RNA
(Additional file 1B).
For all other microinjections, a volume of 4 nl or 5 nl
containing capped mRNA or MOs was injected into one
blastomere of two-cell stage embryos in the following
amounts: hGR (0.5 ng), hGR-XEBF2 (0.5 ng for overex-
pression, 0.1 ng for the MO rescue), hGR-XEBF3 (0.5 ng),
DN-XEBF (2 ng), MyoD-hGR (0.5 ng), nbgal (30 pg),
EBF2 MO (15 ng), EBF3 MO (15 ng) and standard control
MO (30 ng). In the MO experiments, both EBF2 MO and
EBF3 MO were co-injected. For all injections nbgal capped
mRNA was co-injected as a tracer. Embryos were grown
until neurula or tail bud stages [30]. hGR-XEBF2, hGR-
XEBF3 and MyoD-hGR injected embryos were treated
with 30 μM DEX from the gastrula stage (stage 11/11.5) to
the neurula stage (stage 14/15). Embryos were then fixed
with 4% paraformaldehyde in phosphate-buffered saline
for 30 minutes. After washing embryos three times with
phosphate-buffered saline, X-gal staining was performed
as described [31], followed by post-fixation in 4% parafor-
maldehyde for 1 hour at room temperature or overnight
at 4°C.
Microarray analysis
Total RNA was isolated from animal caps with the RNeasy
mini kit (Qiagen, Germantown, MD, USA). This RNA was
used to perform two-color microarray analysis on the
Xenopus Agilent microarray by the University of Utah
Microarray core facility. Fluorescently labeled cRNA, con-
taining either cyanine 3-CTP or cyanine 5-CTP, was gen-
erated using the Agilent Two-Color Quick Amp Labeling
kit (catalog number 5190-0444). Next, microarray hybridi-
zations were performed using Agilent surehyb hybridiza-
tion chambers. Slides were then scanned in an Agilent
Technologies G2505B microarray scanner at 5 μm resolu-
tion. Finally, TIF files were generated from the scanned
microarray image, and loaded into Agilent Feature Extrac-
tion Software version 9.5.1.L O W E S S - n o r m a l i z e dd a t a
from the Feature Extraction software was filtered to
remove control features and features flagged as ‘nonuni-
form’. The LOWESS-normalized intensity values were
loaded into Genesifter software (Geospiza, Seattle, WA,
USA) for analysis. A t-test was applied to data from four
biological replicate experiments. P-values from the t-test
were adjusted for multiple testing using the Benjamini and
Hochberg method. Genes were selected that showed at
l e a s tt w o - f o l dd i f f e r e n t i a le x p r e s s i o na n dh a da d j u s t e d
P-values < 0.05.
In situ hybridization
The following constructs were used to generate antisense
RNA probes: pBS-Xebf2 [8], pBS-Xebf3 [8], pBS-Sox2
[32], PCDH8 (IMAGE ID 6955713, ATCC), Peripherin
(IMAGE ID 4959167, ATCC), GREB1 (IMAGE ID
5569934, ATCC), pBS-XNF-M [8], KCNK5 (IMAGE ID
6863628, ATCC), NSCL-1 (IMAGE ID 5514274, ATCC),
pBS-XNeuroD [33], AML1 (IMAGE ID 4963637, ATCC),
Activin beta B (IMAGE ID 5440215, ATCC), EMX1
(IMAGE ID 6957219, ATCC). Antisense RNA probe was
generated in vitro u s i n gS P 6 ,T 7o rT 3R N Ap o l y m e r a s e
(Ambion) and labeled with digoxigenin-11-UTP (Roche,
Indianapolis, IN, USA). Whole mount in situ hybridiza-
tion was performed on the fixed and X-gal stained
embryos as described [34,35].
Real-time quantitative PCR
For real-time quantitative PCR (RT-QPCR) experiments,
1 ng hGR-XEBF3 mRNA and 0.2 ng Noggin mRNA were
co-injected into Xenopus cells at the one-cell stage and
animal caps were isolated at stage 9. The animal caps were
divided into four groups. The control group received no
treatment (-C-D). The second group was treated with 30
μM DEX alone for 3 hours (-C+D), and the third group
was treated with 5 μg/ml cycloheximide (CHX) alone for
3.5 hours (+C-D). Finally, the fourth group was treated
with 5 μg/ml CHX for 30 minutes and then 30 μMD E X
was added for 3 hours (+C+D). Total RNA was purified
from animal caps with Trizol (Invitrogen) and then geno-
mic DNAs were removed with the RNeasy mini kit
(Qiagen).
To make cDNA from the isolated total RNA from ani-
mal caps, the SuperScript III reverse transcriptase (Invi-
trogen) was used according to the manufacturer’s
instructions, and then QPCR was performed using Power
SYBR Green PCR Master Mix (Applied Biosystems,
Carlsbad, CA, USA) on a 7900HT Real Time PCR System
(Applied Biosystems). Alternatively, the Superscript III
Platinum two step RT-QPCR kit and SYBR Green (Invi-
trogen) were used to make cDNA and to generate the
PCR solution, and QPCR was performed on the same
7900HT Real Time PCR system. MacVector Software
was used to design the gene-specific primers (Additional
file 2). The relative gene expression level was determined
by normalizing the threshold cycle (Ct) of each gene to
the Ct of histone H4. One Ct difference indicates a two-
fold difference in the initial cDNA template amount.
Finally, expression levels were normalized by setting the
expression level in the condition of -C+D to 100.
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Identification of candidate targets of EBF3 in animal caps
To identify transcriptional targets of EBF3, we performed
a microarray screen comparing the transcripts expressed
in Xenopus animal cap ectoderm with and without active
Xenopus EBF3 protein. To control EBF3 activity, we gen-
erated a hormone-inducible fusion protein (hGR-XEBF3)
that can be regulated by the hormone DEX (Additional
file 1A) [26]. We verified that the fusion protein hGR-
XEBF3 replicates EBF3 activity in vivo by demonstrating
that hGR-XEBF3 activated by DEX treatment can induce
ectopic expression of n-tubulin (data not shown) and
neurofilament-m (nf-m) (Figure 1H), similar to unmodi-
fied EBF3 [8]. For all microarrays, we injected mRNA
encoding hGR-XEBF3 into one-cell stage embryos, col-
lected animal caps at the blastula stage, and treated with
DEX for 4.5 hours (to activate hGR-XEBF3 and induce
target gene expression), followed by isolation of total
RNA (Additional file 1B). Control animal caps without
active hGR-XEBF3 were generated in the same way, but
without the addition of DEX.
EBF proteins are involved in the development of B cells,
adipocytes, and muscle cells, as well as of neurons
(reviewed in [13,14,36]), and the activities of EBF are tissue
specific [37]. Since we were interested primarily in neuro-
nal-specific targets of EBF activity, we co-injected embryos
with Noggin mRNA to neuralize the animal caps [27].
Agilent Xenopus microarrays were used to compare target
gene expression levels in DEX-treated animal caps to
those in control DEX-untreated animal caps in four inde-
pendent experiments. To exclude genes that had their
expression levels affected by the hormone DEX alone, we
performed a separate, control microarray analysis using
animal caps treated with DEX expressing control hGR ver-
sus untreated animal caps expressing hGR-XEBF3 (Addi-
tional file 1B). After removal of the small number of genes
that were affected by DEX itself, we found 602 genes that
were upregulated more than two-fold, and 504 genes that
were downregulated more than two-fold by EBF3 activity
(Additional file 3; Gene Expression Omnibus (GEO) acces-
sion [GEO:GSE25734]). We found 242 genes upregulated
more than five-fold, and 115 genes downregulated more
than five-fold.
In cases of incomplete annotation for the Xenopus
microarray, we used NCBI UniGene or BLAST to identify
homologs in other species and determine likely gene iden-
tity. The list of candidate tar g e t si n c l u d e sg e n e sw i t h
known functions in neurons, as well as genes with estab-
lished roles in other tissue types, including muscle. Since
EBF proteins have not previously been implicated in verte-
brate muscle development, an analysis of EBF3 targets
with functions in muscle tissue are described in a separate
study (YS Green and ML Vetter, submitted). An indication
of the integrity of our screen was the strong upregulation
of nf-m, a known EBF3 target gene [8] (Table 1). As a
whole, the results of this array provide an expansive data
set for future study of EBF3 activity in Xenopus.
Classes of candidate target genes with predicted
neuronal function
The list of targets with predicted neuronal function was
very promising, so for further analysis, we selected from
the microarray results 14 genes that were more than 10-
fold upregulated and that we predicted to be involved in
neuronal development, based on expression patterns and
functions known from the published literature, as well as
on our own observations with whole mount in situ hybri-
dization (WM-ISH; discussed below). Although the num-
ber of downregulated genes in our array results is
comparable to the number upregulated, we focused on
upregulated genes for the remaining analysis to identify
potential mediators of EBF function in the nervous system.
The selected EBF3 candidate target genes were classified
b a s e do nt h e i rk n o w no rp r e d i c t e df u n c t i o n s ,a n dt h e s e
are summarized in Table 1. To confirm the microarray
results for these genes, reverse transcriptase PCR (RT-
PCR) was performed using independent animal caps from
those used in the microarray experiments. For each tested
gene, these RT-PCR results showed significant upregula-
tion of gene expression by activated hGR-XEBF3, match-
ing the results found with the microarray analysis (data
not shown). As described in detail later, for a subset of the
genes we performed RT-QPCR using independent sam-
ples, and also found upregulation of gene expression
(Table 1). To determine whether neuralization of the
animal caps was required for EBF regulation of candidate
target genes, we performed an additional microarray
experiment using the same conditions, but without Nog-
gin mRNA co-injection (Additional file 4; GEO accession
[GEO:GSE27084]). We found that all 14 genes were still
upregulated by hGR-XEBF3 in the presence of DEX, sug-
gesting that they can be activated by EBF activity in both
neuralized and non-neuralized ectoderm.
After classification, we found that a large number of the
selected candidate EBF targets are transcription factors -
for example, NR2F2 (nuclear receptor subfamily 2, group
F, member 2, also called COUP-TFII) [38], HOXD10
(homeobox D10, also called HOX4D) [39], NSCL-1 (neu-
ronal stem cell leukemia, also called XHEN1 and NHLH1)
[40], NeuroD [33], EN-2 (engrailed 2) [41], AML1 (acute
myeloid leukemia, also called RUNX1) [42,43], and EMX1
[44]. The fact that we find many transcription factors
strongly upregulated by EBF proteins suggests that there
are multiple levels of transcriptional control that involve
the activity of EBF proteins. For the most part, the remain-
der of the strongly upregulated candidate targets that we
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Page 4 of 18Figure 1 Candidate target genes upregulated by overexpression of EBF2 or EBF3. hGR-XEBF2 or hGR-XEBF3 mRNA was injected into one
cell of two-cell stage embryos, followed by DEX treatment from the late gastrula stage (stage 11/11.5) to the neurula stage (stage 14/15). b-
Galactosidase (b-gal) mRNA was co-injected as a marker of the injected side. In all panels the right side is the injected side, showing the light
blue color of X-gal staining. (A-T) The expression levels of pcdh8 (A,B), peripherin (C,D), greb1 (E,F), nf-m (G,H), kcnk5 (I,J), nscl-1 (K,L), neurod (M,N),
aml1 (O,P), activin beta b (Q,R), and emx1 (S,T) are strongly upregulated by EBF2 and EBF3 (brackets). Panels (A-R) show dorsal views, while (S,T)
show anterior views.
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Page 5 of 18chose are involved in cell structure and neuronal function,
including PCDH8 (protocadherin 8) [45], WNT3a [46],
Peripherin (also called XIF3) [47] and NF-M (Neurofila-
ment-M) [48], KCNK5 (potassium channel subfamily K
member 5, also called TASK2)[ 4 9 ] ,a n dA c t i v i nb e t aB
(also called INHBB) [50], reinforcing the idea that EBF
proteins are involved in neuronal differentiation during
development, as well as performing various functions in
mature neurons.
EBF2 and EBF3 are sufficient for the expression of
candidate neuronal targets in vivo
We previously showed that the protein sequences of Xeno-
pus EBF2 and EBF3, as well as their functions in neuronal
development in Xenopus, are very similar [8]. For these
reasons, we included both EBF2 and EBF3 in the experi-
ments that follow. In order to both confirm the microarray
data and to determine if EBF2 and EBF3 are sufficient for
the expression of the candidate target genes in vivo,w e
examined the expression levels of candidates after overex-
pression of hGR-XEBF2 and hGR-XEBF3. Overexpression
was achieved by injection of mRNA for hGR-XEBF2 or
hGR-XEBF3 into one cell of two-cell stage embryos, fol-
lowed by treatment of the embryos with DEX from the
gastrula stage (stage 11/11.5) to the neurula stage (stage
14/15). The expression level of candidate target genes was
then examined by WM-ISH. We found that 10 of the 14
candidate target genes were upregulated by overexpression
of EBF2 and EBF3 (Figure 1). These were pcdh8 (20/23
embryos by EBF2, 27/28 embryos by EBF3), peripherin
(15/15, 35/35), greb1 (genes regulated by estrogen in
breast cancer; 12/12, 10/10), nf-m (15/15, 35/38), kcnk5
(11/11, 39/40), nscl-1 (9/9, 33/40), neurod (20/21, 39/39),
aml1 (12/12, 11/11), activin beta b (11/11, 37/40), and
emx1 (11/13, 28/32) (Figure 1). However, four genes were
not consistently upregulated by EBF3. The expression of
en-2 (10/19) and hoxd10 (30/44) was downregulated,
while the expression of nr2f2 was upregulated (19/73) in
some embryos but downregulated (30/73) in others, and
the expression of wnt3a (24/24) was not changed by EBF3
(data not shown). We therefore believe that these four
genes are unlikely to be in vivo targets of EBF activity at
this stage of early nervous system development, and we
have excluded them from the experiments that follow.
The fact that the expression levels of 10 genes among 14
candidates are upregulated by overexpression of EBF2 and
EBF3 in the intact embryo supports the microarray data,
and further shows that EBF2 and EBF3 activity are suffi-
cient to drive expression of these candidate genes in vivo.
EBF2 and EBF3 are required for the expression of
candidate targets in vivo
To determine if the expression of our identified candidate
target genes is dependent on EBF2 and EBF3 in vivo,w e
examined the expression levels of candidate targets after
knockdown of EBF2 and EBF3 expression using transla-
tion blocking antisense MOs. EBF2 MO and EBF3 MO
were co-injected into one cell of two-cell stage embryos
and the expression levels of endogenous candidate target
genes were examined at the neurula stage (stage 15/16) or
tailbud stage (stages 25 to 28), when expression of candi-
date target genes is apparent (Figures 2 and 3). We first
confirmed that expression of the neural plate marker sox2
was not changed (10/10 embryos; Figure 2B), indicating
Table 1 Candidate targets of EBF activity
Gene name Function FC
1
(microarray)
FC
2
(RT-QPCR)
GenBank
pcdh8 Transmembrane protein 66 93
a BC074360
nr2f2 Nuclear receptor TF 47 ND BC078057
wnt3a Wnt signaling ligand 45 ND L07538
peripherin Type III intermediate filament 37 32
a BC056020
greb1 Estrogen-regulated gene 32 21
b BC043838
hoxd10 Homeodomain TF 31 ND BC061944
nf-m Type IV intermediate filament 28 29
b BC078128
kcnk5 K+ ion channel 27 6
b BC084931
nscl-1 bHLH TF 26 7
b BC084434
neurod bHLH TF 26 164
b BC072996
en-2 Homeodomain TF 24 ND X62974
aml1 Runt-related TF 22 24
a BC057739
activin beta b TGF-beta superfamily member 21 154
b S61773
emx1 Homeodomain TF 16 15
b BC077629
The genes chosen for analysis are shown with their known functional roles. FC
1 refers to the average fold change in expression by microarray analysis after DEX
treatment for 4.5 hours compared to control, in four replicate experiments. FC
2 refers to the fold change in expression after DEX treatment for 3 hours compared
to control, as detected by RT-QPCR using independent samples (see Figure 6 and Additional file 6 for details).
aPerformed three replicate experiments;
bperformed once. FC, fold change; ND, not determined; TF, transcription factor.
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Page 6 of 18Figure 2 Downregulation of transcription factor candidate target genes after knockdown of EBF2 and EBF3. One cell of two-cell stage
embryos was injected with either control MO, both EBF2 MO and EBF3 MO (2MO + 3MO), or dominant negative Xenopus EBF3 (DN-XEBF)
mRNA. b-Galactosidase (b-gal) mRNA was co-injected as a marker of the injected side. In all panels the right side is the injected side, showing
the light blue color of X-gal staining. (A-C) The expression of sox2 was not changed in all three conditions. (D-O) The expression of nscl-1 (E,F),
neurod (H,I), aml1 (K,L), and emx1 (N,O) is downregulated by EBF2 MO and EBF3 MO, and by DN-XEBF (brackets), while control MO does not
change their expression levels (D,G,J,M). Panels (A-L) show dorsal views of neurula stage embryos (stage 15/16), and (M-O) are anterior views of
tail bud stage embryos (stages 25 to 28).
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Page 7 of 18Figure 3 Downregulation of non-transcription factor candidate target genes after knockdown of EBF2 and EBF3. One cell of two-cell
stage embryos was injected with either control MO, both EBF2 MO and EBF3 MO (2MO + 3MO), or dominant negative Xenopus EBF3 (DN-XEBF)
mRNA. b-Galactosidase (b-gal) mRNA was co-injected as a marker of the injected side. In all panels the right side is the injected side, showing
the light blue color of X-gal staining. (A-R) The expression of pcdh8 (B,C), peripherin (E,F), greb1 (H,I), nf-m (K,L), kcnk5 (N,O), and activin beta b (Q,
R) is downregulated by EBF2 MO and EBF3 MO, and by DN-XEBF (brackets), while control MO does not change their expression levels (A,D,G,J,M,
P). Panels (A-I) and (P-R) are neurula stage embryos (stage 15/16), and (J-O) are tail bud stage embryos (stages 25 to 28). All panels show dorsal
views.
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Page 8 of 18that knockdown of EBF2 and EBF3 did not affect early
global neuronal development in the early embryos. After
co-injection of EBF2 MO and EBF3 MO, the expression of
nscl-1 (10/11), neurod (13/15), aml1 (7/12), emx1 (12/15),
pcdh8 (12/13), peripherin (11/11), greb1 (11/12), nf-m
(14/16), kcnk5 (10/15) and activin beta b (5/10) were
downregulated (Figures 2 and 3). Control MO did not
change the expression levels of these genes (Figures 2 and
3). The expression of peripherin was partially rescued by
co-injecting EBF2 MO and EBF3 MO together with
mRNA for hGR-XEBF2, which does not have overlapping
sequence with the MOs, and then treating with DEX from
the gastrula stage (stage 11.5) to the neurula stage (stage
15/16) (Additional file 5). This control demonstrates that
the EBF2 MO and EBF3 MO specifically block EBF
activity.
To confirm the MO results, we generated a dominant
negative Xenopus EBF3 construct (DN-XEBF). This DN-
XEBF (amino acids 349 to 598) lacks the DNA binding
domain in the amino-terminal region, but it has an
intact dimerization domain [ 4 , 7 , 1 2 ] .S i n c eE B F 1 ,2 ,a n d
3 can form homodimers or heterodimers in vitro
[2,4,12], this DN-XEBF is predicted to block the func-
tion of both EBF2 and EBF3 by forming non-functional
dimers. Similar to our MO data, injection of mRNA
encoding DN-XEBF led to downregulation of the
expression of nscl-1 (5/13 embryos), neurod (12/18),
aml1 (6/14), emx1 (7/15), pcdh8 (8/18), peripherin
(8/13), greb1 (8/14), nf-m (10/19), kcnk5 (7/19) and acti-
vin beta b (8/17) (Figures 2 and 3) while sox2 expression
was not changed by DN-XEBF at the neurula stage
(13/14) (Figure 2C). However, the level of downregula-
tion of candidate target genes was weaker than that
obtained by MO injection, perhaps because some endo-
genous EBF protein is able to form normal dimers even
in the presence of DN-XEBF. In addition, a majority of
embryos became bent toward the injected side at the
tailbud stage because this side was smaller than the
uninjected side (data not shown), suggesting changes in
the development of other tissues. Taken together, these
function-blocking experiments with MOs and DN-XEBF
suggest that EBF2 and EBF3 are required for the expres-
sion of our neuronal candidate targets in vivo.
Comparison of the expression patterns of EBF2, EBF3 and
their candidate targets in the Xenopus nervous system
To determine if the functional relationships we identified
above might be indicative of in vivo genetic relationships
between ebf genes and candidate targets, and to deter-
mine if the candidate targets have expression patterns
consistent with a role in neuronal development, we com-
pared the expression domains of ebf2 and ebf3 with those
of candidate target genes by WM-ISH at four different
stages in early Xenopus embryos: stage 12.5 (data not
shown), 15, 23 and 28 (Figures 4 and 5). We chose these
stages because the expression of ebf2 is visible from stage
12.5, the expression of ebf3 is clearly visible at stage 15,
and their expression continues beyond stage 28 [7,8].
ebf2 and ebf3 are expressed in very similar neuronal tis-
sues (Figure 4A-F). At stage 15, both are expressed in the
three stripes (medial, intermediate, and lateral) of pri-
mary neurons in the neural plate and trigeminal pla-
codes. At stage 23, both are expressed in the trigeminal
placodes, the olfactory placodes, spinal cord, and neural
crest derivatives, including branchial arches. By stage 28,
their expression expands to encompass much of the
developing brain.
First, we compared the expression patterns of ebf genes
and the candidate targets that are known transcription
factors since a number of candidate target genes fell into
this category (Figure 4). The expression patterns of both
bHLH transcription factors, nscl-1 (Figure 4G-I) [40] and
neurod (Figure 4J-L) [33], overlap strongly with those of
ebf2 and ebf3 in the three stripes of primary neurons, tri-
geminal placodes, olfactory placodes and spinal cord.
In Xenopus embryos, the neuronal expression of aml1
(Figure 4M-O) [42,43] is limited to sensory neurons,
including the lateral stripe ats t a g e1 5 ,s e n s o r yn e u r o n s
in the spinal cord at stage 23, and olfactory placode at
stage 28, and this expression pattern overlaps with the
expression of ebf2 and ebf3. The expression of emx1
(Figure 4P-R) [44] in the dorsal forebrain region at stages
23 and 28 overlaps with the expression of ebf2 and ebf3.
Second, we compared the expression patterns of ebf
genes and the candidate targets that do not have tran-
scriptional activity, and that were predicted to play a role
in cell structure and neuronal function (Figure 5). The
expression of pcdh8 (Figure 5A-C) does partially overlap
with that of ebf2 and ebf3 in two stripes of primary neu-
rons, spinal cord, midbrain, and hindbrain. The neuronal
intermediate filament genes peripherin (Figure 5D-F) [51]
and nf-m (Figure 5J,K) [52] show strongly overlapping
expression patterns with ebf2 and ebf3 in the three stripes
of primary neurons, trigeminal placodes, olfactory pla-
codes and spinal cord from the earliest stages in which
they are expressed. The expression patterns of greb1
(Figure 5G-I), kcnk5 (Figure 5L-N) and activin beta b
(Figure 5O-Q) [50] do not overlap with those of ebf2 and
ebf3 at stage 15, but partially overlap in some domains in
the brain or the spinal cord at stages 23 or 28.
In summary, the candidate EBF target genes show com-
plex patterns of expression during nervous system devel-
opment with different degrees of overlap with the EBF
factors. For example, some were highly overlapping, nscl-
1, neurod, aml1, peripherin,a n dnf-m, while others
showed more limited overlap, such as emx1, pcdh8,
greb1, kcnk5,a n dactivin beta b. The genes pcdh8, greb1,
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Page 9 of 18Figure 4 Neuronal expression for ebf genes and transcription factor candidate target genes. (A-F) ebf2 (A-C) and ebf3 (D-F) are expressed
in multiple regions of the developing nervous system, including the trigeminal placodes (yellow arrows), olfactory placodes (black arrows), some
domains in the brain, the spinal cord (white arrows), and neural crest derivatives like the branchial arches. (G-L) nscl-1 (G-I) and neurod (J-L) are
expressed in the trigeminal placodes and three stripes of primary neurons in the neural plate (black arrowheads) at stage 15, and are strongly
expressed in the trigeminal placodes, olfactory placodes, and spinal cord at stage 23. At stage 28, nscl-1 is expressed in the olfactory placodes,
some domains in the midbrain/hindbrain, spinal cord and cranial ganglia IX and X. At stage 28, neurod is expressed in the olfactory placodes,
retina, otic placodes, cranial ganglia, spinal cord and some domains in the brain. (M-O) aml1 is expressed in the lateral primary neuron stripe at
stage 15, sensory neurons of the spinal cord (white arrowheads) at stage 23, and the olfactory placodes and otic placodes at stage 28. (P-R)
emx1 is weakly expressed in the prospective forebrain region at stage 15. At stages 23 and 28, this gene is expressed in the dorsal forebrain
region. Stage 15 embryos show dorsal views except (P) (anterior view). Stage 23 and 28 embryos show lateral views.
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Page 10 of 18Figure 5 Neuronal expression for non-transcription factor candidate target genes. (A-C) pcdh8 is expressed in medial and intermediate
stripes (arrowheads) of primary neurons, in one posterior stripe between the two stripes of primary neurons, and in the anterior domain of the
neural plate at stage 15, and in the spinal cord (white arrows) and some domains in the brain at stages 23 and 28. (D-F) peripherin is expressed
in the trigeminal placodes (yellow arrows) and three stripes of primary neurons (arrowheads) at stage 15, and in the trigeminal placodes,
olfactory placodes (black arrow), spinal cord, retina and many domains in the brain at stages 23 and 28. (G-I) greb1 is expressed as a band in the
prospective midbrain/hindbrain region at stage 15, and in the midbrain/hindbrain region and spinal cord at stage 23, and in the olfactory
placodes, spinal cord, and many domains in the brain at stage 28. (J,K) nf-m is not expressed at stage 15, but at stages 23 and 28 it is expressed
in the trigeminal placodes and spinal cord. (L-N) kcnk5 is weakly expressed from anterior to posterior along the dorsal midline, with stronger
expression in the anterior end of the neural fold at stage 15. It is expressed in retina, otic placode, and several domains in the brain at stages 23
and 28, and in spinal cord at stage 28. (O-Q) activin beta b is expressed in two bands in the prospective midbrain/hindbrain region and diffusely
throughout the anterior neural plate at stage 15, and it is expressed in the retina and some brain domains at stages 23 and 28. Stage 15
embryos show dorsal views, and stages 23 and 28 embryos show lateral views.
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Page 11 of 18and kcnk5 have not previously been described during
Xenopus neuronal development.
Identification of direct candidate targets for EBF3 in
animal caps by RT-QPCR
To better understand the transcriptional interaction
between EBF3 and its candidate target genes, we sought
to identify which genes are direct transcriptional candi-
date targets and which are indirect transcriptional candi-
date targets. We used an approach similar to the
microarray analysis, with DEX treatment of animal caps
to drive activation of hGR-XEBF3, but we added CHX
to block protein synthesis, so that only direct EBF3 can-
didate targets should be transcribed. Animal caps were
collected at stage 9 after injection of hGR-XEBF3, and
divided into four groups: untreated control (-C-D), DEX
alone (-C+D), CHX alone (+C-D), and both CHX and
DEX (+C+D). All animal caps were collected after a 3.5-
hour incubation. CHX treatment lasted the entire 3.5
hours, while DEX treatment started after a 30-minute
delay to allow time for CHX to take effect. The expres-
sion level of each candidate target was examined by RT-
QPCR (Table 1 and Figure 6; Additional file 6). We nor-
malized the expression level of candidate target genes
with that of histone h4, and for Figure 6 and Additional
file 6 we set the normalized expression level in the con-
dition of -C+D to 100% (see Materials and methods).
After treatment with both CHX and DEX, candidate
targets that had expression levels of less than 10% of the
level in animal caps treated with DEX alone (or candi-
dates that had expression levels similar to untreated
controls, even if that was greater than 10% of the DEX
alone condition) were considered to be indirect candi-
date targets. These indirect targets are pcdh8, kcnk5,
activin beta b, neurod and greb1 (Figure 6B; Additional
file 6D-G). Candidate target genes with expression levels
of greater than 50% of the levels in animal caps treated
with DEX alone are candidate targets for which the
majority of their expression is directly controlled by
EBF3. These include peripherin, emx1 and nf-m (Figure
6A; Additional file 6AB). Finally, there are genes with
expression levels between 10 and 50% of the level in
animal caps treated with DEX alone. These genes,
including aml1 and nscl-1,l i k e l yh a v es o m ee x p r e s s i o n
that is under direct regulation by EBF3 (Figure 6C;
Additional file 6C), suggesting that their expression is
controlled not only by EBF3 directly but also through
other targets of EBF3.
Figure 6 The identification of direct and indirect candidate targets of EBF3 by RT-QPCR. hGR-XEBF3 mRNA and Noggin mRNA were
injected into one-cell stage embryos, and animal caps were collected at the blastula stage (stage 9). The animal caps were divided into four
groups, based on CHX and DEX treatment: -C-D, -C+D, +C-D, and +C+D. After a 3.5-hour incubation with CHX and/or a 3-hour incubation with
DEX, total RNA was isolated from each animal cap group. RT-QPCR was conducted with the isolated total RNA. The expression level was
normalized with the expression level of histone h4 and then normalized to the expression level of -C+D, for each gene, at 100 arbitrary units. (A-
C) The expression levels of all candidate target genes in controls (-C-D and +C-D) are very low compared to the DEX-treated condition of -C+D.
(A) The expression level of peripherin in +C+D (61%) is only partially reduced compared to -C+D, indicating that the majority of its expression is
controlled by EBF3 directly. (B) The expression level of pcdh8 in +C+D (5%) is much lower than in -C+D and is similar to the levels of the control
conditions, indicating that it is an indirect candidate target. (C) The expression level of aml1 in +C+D (37%) is lower than the expression level in
-C+D but higher than levels of the control conditions, indicating that its expression is partially controlled by EBF3 directly. Error bars represent
standard error of the mean. The results for the remaining candidate target genes are shown in Additional file 6. N = 3 replicates, 20 to 30 animal
caps per condition.
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To better understand the range of activities that are driven
by EBF transcription factors during neural development,
we used a systematic approach to identify candidate target
genes of EBF activity in Xenopus. In this study, we empha-
size candidate targets that were highly upregulated by EBF
activity by microarray analysis and with potential functions
in neuronal development. Our microarray screen for
targets of EBF transcriptional activity revealed many genes
that were previously not known to be targets of EBF activ-
ity. Ten of the genes showed upregulation after EBF over-
expression, and downregulation after EBF knockdown in
neurula or tailbud stage embryos, demonstrating their
in vivo dependence on EBF activity. In addition, all ten of
these genes partially overlap in their expression with ebf
genes, consistent with regulation by EBF proteins during
neural development. Since some of these genes are direct
targets with partial dependency on EBF activity, others are
indirect candidate targets, and most have only partially
overlapping expression with ebf genes, it is clear that EBF
proteins are part of a more complex transcriptional regula-
tory network involved in driving their expression. The
candidate target genes we identified by microarray analy-
sis, but did not characterize further, also have the potential
to reveal involvement of EBF proteins in additional activ-
ities, and this list of genes should aid future research into
EBF functions.
Several previous studies, including EBF gain- and loss-
of-function studies in Drosophila, C. elegans, ebf mutant
mice, chicks, Xenopus, and in cell lines, have revealed a
number of neuronal genes that are regulated by EBF tran-
scriptional activity [2,7,8,15-17,19,53-56]. With the excep-
tion of nf-m, the list of candidate EBF target genes that we
selected for analysis does not include these previously
described EBF-regulated genes. However, among the addi-
tional genes from the microarray that are upregulated by
EBF activity we found lhx9 and lmo4, which are homolo-
gous to apterous, a known target of Collier in Drosophila
[17]. It is likely that we did not recognize the presence of
other known EBF target genes in our array results due to
the incomplete annotation of the Xenopus microarray.
Another explanation could be that expression of these tar-
gets is driven by EBF in the more differentiated environ-
ments of each independent experiment, but not in the
relatively naïve environment of Xenopus animal caps.
Future improvements in Xenopus annotation should
make it possible to help distinguish between these two
explanations.
We find in our Xenopus EBF screens comparable
numbers of strongly downregulated genes and strongly
upregulated genes. This parallels the important roles
shown for EBF proteins functioning as transcriptional
repressors to help determine cell fate in cell types such
as B cells in mice [37,57,58] and ASI chemosensory neu-
rons in C. elegans [55]. As part of a future study, it will
be interesting to see the extent to which our candidate
downregulated genes are related to cell fate.
EBF proteins are involved in the development of multi-
ple lineages, including B cells and adipocytes. Interestingly,
in our array analysis we found genes with known roles in
non-neuronal tissue types like myod, which regulates mus-
cle development, or lmo2 and hex, which are involved in
leukocyte development. These genes were upregulated
even after animal caps were neuralized with Noggin. Thus,
in the relatively naïve environment of animal cap ecto-
derm it may be permissive for EBF target genes from mul-
tiple lineages to be expressed. EBF proteins have been
proposed to function as pioneer factors for B cell genes in
hematopoietic lineages [37]. Therefore, EBF factors may
alter chromatin to permit genes involved in lineage specifi-
cation and differentiation to be expressed. There have
been screens performed to identify targets of EBF proteins
in non-neuronal cell types such as B cells and adipocytes
[37,59,60]. A detailed comparison of our array results with
these studies is difficult since limited annotation of the
Xenopus arrays precludes systematic cross-species
comparisons.
EBF regulation of multiple transcription factor genes
suggests involvement in extensive transcriptional
networks for neuronal development
Our finding that several transcription factors are among
the strongest candidate targets of EBF activity expands
the potential means by which EBF activity could exert its
many effects on neuronal development, and also suggests
some interesting new potential functions. The bHLH
transcription factor NSCL-1 can drive expression of the
proneural bHLH transcription factor NGNR-1, which is
important for neuronal cell commitment in Xenopus
embryos [40,61]. In chick and mouse, NSCL-1 can pro-
mote neuronal cell differentiation, and migration of cellu-
lar populations, including GnRH-1 neurons [62-64].
Interestingly, Ebf2 knockout mice show a migration
defect of GnRH-1 neurons [21]. We find that the expres-
sion of nscl-1 is partially under the direct control of EBF
activity, and that the expression patterns of nscl-1 and ebf
genes strongly overlap. This suggests that EBF activity
may act through NSCL-1 to regulate neuronal cell com-
mitment, differentiation or migration.
The well-known functions of the proneural bHLH
transcription factor NeuroD in multiple species show
that it is involved primarily in differentiation, but also
acts to regulate cell fate, cell migration and cell survival
[33,65-68]. This study and previous studies show that
neurod expression is very similar to that of ebf genes
[7,8,33]. Previous studies showed that neurod is both
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Xenopus embryos [7,8,28,65]. Our present data suggest
that neurod is also an indirect candidate target of EBF3.
Together, these results support and expand the concept
of multiple transcriptional interactions between EBF pro-
teins and NeuroD [7,8,28,65].
AML1, a runt related transcription factor, is known to
be expressed in neurons, including cortical progenitors,
olfactory receptor progenitors and neurons in the dorsal
root ganglia and to be involved in differentiation and cell
type specification of several types of sensory and motor
neurons, including neurons in the dorsal root ganglia
[42,69-71]. Interestingly, AML1 is known to cooperate
with EBF proteins in B cell development [72]. We find
that aml1 is partially under the direct control of EBF activ-
ity, and that the expression patterns of aml1 and ebf genes
overlap strongly in the nervous system. Thus, AML1 and
EBF proteins may also act cooperatively in promoting neu-
ronal differentiation.
In multiple species, the homeobox transcription factor
Emx1 is strongly expressed in the developing forebrain,
and the EMX1 protein is present in the axons of the olfac-
tory neurons [44,73,74]. Compared to Emx2 knockout
mice, Emx1 knockout mice show only minor defects in
brain development [75-77]. However, Emx1 and Emx2
double mutant mice show more severe defects than Emx2
knockout mice, including defects of neuronal differentia-
tion and thalamocortical pathfinding [78], similar to those
found in Ebf1 knockout mice [16]. Since we find emx1 to
be a strong, direct candidate target of EBF proteins, and
emx1 and ebf genes are both strongly expressed in the
forebrain, EBF proteins may control cell differentiation
and axon growth in part by driving expression of emx1.
EBF proteins drive expression of candidate targets
involved in multiple aspects of neuronal differentiation
The candidate targets that are not transcription factors
illuminate some of the ways that EBF activity could help
regulate late steps of neuronal differentiation and neuro-
nal function. Peripherin and NF-M are important com-
ponents of neuronal intermediate filaments, which help
to form the cytoskeleton in the cell body and neurites of
neurons [79-82]. We find that the majority of expression
of peripherin and nf-m is controlled directly by EBF3,
and that their expression strongly overlaps with that of
ebf genes. These discoveries correlate with previous evi-
dence showing axonal pathfinding defects of thalamocor-
tical and olfactory receptor neurons in Ebf null mice,
pathfinding defects of motor neurons in C. elegans UNC-
3 mutants, and problems with dendritic arborization in
Drosophila Collier mutants [11,16,19,20,53,54,83]. These
correlations both support a role for EBF proteins in axon
growth or stability and provide a potential additional
route for exploration of how EBF proteins can affect this
important process.
PCDH8 is a transmembrane calcium-dependant adhe-
sion molecule. The rat homolog Arcadlin affects the num-
ber of dendritic spines in cultured hippocampal neurons
[84] and is required for activity-induced long-term poten-
tiation [85]. We find that EBF proteins positively regulate
the expression of a gene that is likely the Xenopus pcdh8
homolog (based on sequence similarity and similar range
of gene expression with mouse Pcdh8 in midbrain, hind-
brain and spinal cord [86]). We show that pcdh8 is an
indirect candidate target of EBF activity, and that pcdh8
and ebf expression patterns overlap in the brain and spinal
cord, suggesting that EBF proteins may be involved in
synaptic plasticity by controlling the expression of pcdh8,
which would be a new function for EBF proteins in the
nervous system.
KCNK5 is a K+ channel that is sensitive to extracellular
pH, and in rat kidney cells it functions to stabilize bicarbo-
nate transport and control cell volume [49,87,88]. It
appears to be involved in maintaining the membrane
potential of chemoreceptor cells in mouse brainstem [89].
We find that Xenopus kcnk5 is indirectly upregulated by
EBF activity. In addition, we find overlap between ebf and
kcnk5 gene expression in the midbrain and hindbrain at
the tailbud stage. Regulation of this gene represents a pre-
viously unknown function for EBF transcriptional activity.
Activin beta B forms homodimers, or heterodimers
with Activin beta A. Activins are ligands of the TGF-beta
superfamily, which are involved in differentiation in tis-
sues from many systems, including the reproductive sys-
tem [90-93]. Activin beta B is expressed in the
developing brain and retina ([50,94,95] and our data), but
its function in neuronal development is not yet clear.
Our study shows that the activin beta b gene is likely an
indirect candidate target of EBF proteins, and that its
expression precedes that of ebf genes in midbrain, hind-
brain and retina. These results suggest that EBF activity
may maintain the expression of activin beta b instead of
initiating its expression.
The protein GREB1 is thought to be involved in the
estrogen-induced growth of breast cancer cells [96,97],
but its function is not known, and its expression pattern
in animal development has not been previously
described. We find that greb1 is expressed in several tis-
sues, including neurons and muscle cells, during Xeno-
pus development. Overlapping expression with ebf genes
is limited to the spinal cord and a few brain regions at
tailbud stages, and we find that the expression of greb1
is controlled by EBF proteins indirectly. Our findings
demonstrate a potential relationship between these
g e n e sa n dap o s s i b l er o l ef o rG R E B 1i nn e u r o n a l
development.
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to be direct targets
Interestingly, the candidate targets having direct depen-
dency on EBF3 for their expression, based on our CHX
experiments (Figure 6; Additional file 6), tended to have
the most overlap with ebf genes in their WM-ISH
expression patterns (Figures 4 and 5). These included
the genes that code for axonal structural proteins (per-
ipherin and nf-m) and two that code for transcription
factors (aml1 and nscl-1). In contrast, the genes that
appear to be indirect candidate targets tended to be
those that have the least overlap with ebf genes in their
expression patterns. These included pcdh8, kcnk5, acti-
vin beta b, and greb1. An exception to this rule was neu-
rod, which has extensive overlap with ebf genes, but is
an indirect target. This could reflect the fact that neurod
is also upstream of ebf genes [7,8,28,65]. These results
strengthen the conclusion that in vivo expression of the
candidate target genes determined to have direct depen-
dency on EBF3 transcriptional activity is likely to be
heavily dependent on EBF activity.
EBF proteins function in cell commitment and
differentiation in the development of multiple lineages
EBF proteins have been implicated in the specification,
commitment, and differentiation of specific cell types by
regulating the expression of both genes in transcrip-
tional regulatory networks as well as genes involved in
the functional activities of a cell type, consistent with
what we found in our analysis. For example, EBF1 is
known to participate in B cell specification, commit-
ment, and differentiation by inducing the expression of
transcription factors like E2A (Tcf3) and Pax5, and non-
transcription factors like CD79a (mb-1) and VpreB
[37,60,98,99]. EBF proteins similarly participate in adipo-
cyte differentiation, by inducing the expression of both
types of genes [59,100,101].
In B cells EBF1 acts cooperatively with other tran-
scription factors, including AML1 (RUNX1), E2A, Pax5,
and Foxo1, by driving expression of overlapping sets of
target genes ([102] and reviewed in [36,103-105]). Inter-
estingly, these transcription factors are themselves tar-
gets of EBF1 in B cells. Similar mechanisms are found
during neuronal subtype development in the Drosophila
ventral nerve cord [17]. The fact that AML1 is also one
of our candidate targets, and that most of our transcrip-
tion factor candidate targets have extensive and early
co-expression with ebf2 and ebf3, suggests that EBF pro-
teins may act cooperatively with their transcription fac-
tor targets for the expression of some genes in Xenopus
neuronal development. Cooperative regulation of gene
expression could be part of positive feedback mechan-
isms that solidify cell commitment choices and differen-
tiated states.
EBF2 and EBF3 appear to share most candidate targets
during early Xenopus development
In the developing mouse nervous system, there is evi-
dence for areas of overlap in the functions of different
members of the EBF family. For example, Ebf2 and Ebf3
knockout mice have similar phenotypes for olfactory
axon growth [20], and Ebf1 null mice do not show
severe defects in the brain regions expressing multiple
EBF family members concomitantly [1,2,5,16,98]. How-
ever, there is also evidence for distinct functions of dif-
ferent members, including the fact that Ebf1 is the only
member expressed in the embryonic striatum and Ebf1
null mice show defective neuronal cell differentiation in
that region [1,16]. In addition, Ebf2 null mice show
defective migration of GnRH-1 neurons even though
Ebf1 is also expressed in those neurons [21,106]. In
Xenopus, the previously known functions of EBF2 and
EBF3 are very similar during early development [7,8].
They are both important for neuronal differentiation,
including control of the expression of the neuronal spe-
cific markers N-tubulin, N-CAM, and NF-M. Support-
ing the similarity of the roles of these two genes, we
find that the ten candidate targets of EBF3 that were
upregulated by hGR-XEBF3 in Xenopus animal caps and
in vivo could also be upregulated by hGR-XEBF2 in
vivo. Although there is interesting evidence for some
differences in expression patterns and functions of EBF2
and EBF3 [7,8], our results support the idea that EBF2
and EBF3 have largely redundant functions at the tran-
scriptional level.
Conclusions
We have found multiple EBF candidate targets using a sys-
tematic approach in Xenopus embryos. The expression
patterns of direct candidate targets of EBF3 have strong
overlap with ebf gene expression, while candidate targets
having largely indirect dependency on EBF3 are expressed
in less overlapping patterns, suggesting more complex
modes of regulation. The novel candidate target genes
suggest new potential routes for EBF transcription factors
to carry out their previously known functions of neuronal
cell commitment, differentiation, neurite formation and
migration, and also suggest some new potential functions
of EBF activity.
Additional material
Additional file 1: Hormone inducible constructs and scheme of
microarray screens. (A) Schematic diagram of the hormone inducible
constructs used in the microarrays. (B) Schematic representation of the
microarray screen comparing transcripts in DEX-treated animal caps (with
activated hGR-XEBF3) and untreated animal caps (without activated hGR-
XEBF3), as well as the control array to analyze the effects of DEX
treatment. The scheme shown represents the arrays performed in the
presence of Noggin mRNA.
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Additional file 3: Microarray results table showing genes up- or
downregulated more than two-fold by EBF3 activity in the
presence of Noggin.
Additional file 4: Microarray results table showing genes up- or
downregulated more than two-fold by EBF3 activity in the absence
of Noggin.
Additional file 5: Expression of peripherin in embryos treated with
EBF2 MO and EBF3 MO can be rescued by co-injection of hGR-
XEBF2. One cell of two-cell stage embryos was injected with EBF2 MO,
EBF3 MO and mRNA encoding hGR-XEBF2, followed by DEX treatment
(or no treatment in controls) from the late gastrula stage (stage 11.5) to
the neurula stage (stage 15/16). b-Galactosidase (b-gal) mRNA was co-
injected as a marker of the injected side. In both panels the right side is
the injected side (brackets). In control embryos (without DEX treatment)
peripherin expression was downregulated either strongly (3/7, shown in
(A)) or weakly (4/7, not shown) compared to the uninjected side due to
the MO effect. In the majority of DEX-treated embryos peripherin
expression was either rescued (16/34, shown in (B)), or only weakly
downregulated (17/34, not shown). Both panels show dorsal views.
Additional file 6: Additional identification of direct and indirect
candidate targets of EBF3 by RT-QPCR. Expression levels for the
remaining candidate target genes tested by RT-QPCR after CHX and DEX
treatment (those not shown in Figure 6). (A,B) The expression levels of
emx1 (88%) and nf-m (56%) in +C+D are slightly lower than in -C+D,
indicating that the majority of their expression is controlled by EBF3
directly. (C) The expression level of nscl-1 (46%) in +C+D is lower than in
-C+D but higher than that in the two controls, indicating that its
expression is under partial direct control of EBF3. (D-G) The expression
levels of kcnk5 (20%), activin beta b (10%), neurod (8%) and greb1 (1%) in
+C+D are similar to control levels (D) or much lower (less than 10%)
than in -C+D (E-G). N = 20 to 30 animal caps per condition.
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